Publicaciones en colaboración con investigadores/as de Hospital Universitario San Cecilio (48)

2024

  1. The HIV-1 reservoir landscape in persistent elite controllers and transient elite controllers

    Journal of Clinical Investigation, Vol. 134, Núm. 8

  2. Transmitted Drug Resistance and HIV Diversity Among Adolescents Newly Diagnosed With HIV in Spain

    Pediatric Infectious Disease Journal, Vol. 43, Núm. 1, pp. 40-48

2022

  1. Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals

    JHEP Reports, Vol. 4, Núm. 5

  2. Rildo: Real-World Multicenter Study on the Effectiveness and Safety of Single-Tablet Regimen of Dolutegravir plus Rilpivirine in Treatment-Experienced People Living with HIV

    Viruses, Vol. 14, Núm. 12

2021

  1. Empirical treatment with doxycycline of fever of intermediate duration

    European Journal of Clinical Microbiology and Infectious Diseases

  2. Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy

    Journal of Hepatology, Vol. 74, Núm. 4, pp. 801-810

  3. Hemophagocytic lymphohistiocytosis associated with Leishmania: A hidden passenger in endemic areas

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 39, Núm. 4, pp. 188-191

2020

  1. Clinically atypical cutaneous mycobacteriosis: A therapeutic challenge

    Dermatologic Therapy, Vol. 33, Núm. 6

  2. Evolution and treatment of storm cytoquine syndrome associated to SARS-CoV-2 infection among octogenarians

    Revista Espanola de Geriatria y Gerontologia, Vol. 55, Núm. 5, pp. 286-288

  3. Imported babesiosis caused by Babesia microti—A case report

    Ticks and Tick-borne Diseases

  4. Necrotizing Sarcoid Granulomatosis: A Disease Not to be Forgotten

    Case Reports in Medicine, Vol. 2020

  5. Primary resistance to integrase strand transfer inhibitors in Spain using ultrasensitive HIV-1 genotyping

    Journal of Antimicrobial Chemotherapy, Vol. 75, Núm. 12, pp. 3517-3524

2019

  1. Rapid decrease in titer and breadth of neutralizing anti-HCV antibodies in HIV/HCV-coinfected patients who achieved SVR

    Scientific Reports, Vol. 9, Núm. 1

2018

  1. Dysregulation of the immune system in HIV/HCV-coinfected patients according to liver stiffness status

    Cells, Vol. 7, Núm. 11

2017

  1. Prediction of long-term outcomes of HIV-infected patients developing non-AIDS events using a multistate approach

    PLoS ONE, Vol. 12, Núm. 9

  2. Simplification to dual therapy (atazanavir/ritonavir1lamivudine) versus standard triple therapy [atazanavir/ritonavir1two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)

    Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 1, pp. 246-253

2016

  1. Impact of late presentation of HIV infection on short-, mid- and long-term mortality and causes of death in a multicenter national cohort: 2004-2013

    Journal of Infection, Vol. 72, Núm. 5, pp. 587-596

  2. MicroRNA profile in CD8+ T-lymphocytes from HIV-infected individuals: Relationship with antiviral immune response and disease progression

    PLoS ONE, Vol. 11, Núm. 5

2015

  1. Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial

    The Lancet Infectious Diseases, Vol. 15, Núm. 7, pp. 775-784

  2. Nebulized medication is not associated with nosocomial infections. A pilot study

    Revista Espanola de Quimioterapia, Vol. 28, Núm. 3, pp. 154-156